Area-level Socioeconomic Status Research Articles

Evaluating the impact ofthe Community Helpers Program on adolescents 12-18 years old in Edmonton, Canada.

Alberta Health Services (AHS) Community Helpers Program (CHP) to enhance mental health among youth. Identifying the impact of CHP on mental illness-related acute care use among adolescents aged 12-18 years in Edmonton and determining cost avoidance. Using administrative data from AHS, public school catchment area data from theEdmonton Public School Board, and area-level socioeconomic deprivation status indicators from the Pampalon deprivation index, we applied geographical regression discontinuity design to estimate the effect of CHP implementation on depression-, anxiety-, and suicide-related acute care use (emergency department visits and inpatient admissions). Cost data were derived from Interactive Health Data Application of Alberta Health. The study period (2002-2022) included pre (2002-2011) and post (2012-2020) CHP implementation periods. CHP had statistically significant impact when distance from the boundary (catchment area identifier to divide the sample into treated and control groups) was between 600 and 800 m. About 90 and 80 fewer anxiety- and depression-related visits (per 1000 visits) were observed among individuals aged 12-15 and 16-18 years, respectively, in catchment areas of the public schools where CHP was implemented. Impact of CHP on suicide-related visits was only statistically significant among individuals aged 12-15 years. Annual cost reduction ranged from $161,117 to $269,255 for anxiety- and depression-related visits. Findings show contextual effect of CHP; i.e., being potentially exposed to the program reduced the likelihood of anxiety- and depression-related visits. Costs of CHP implementation could be compared with the avoided costs to assess economic benefits of implementing CHP.

Estimating the Impact of Rurality in Disparities in Cancer Mortality.

Estimation of the independent effect of rurality on cancer mortality requires causal inference methodology and consideration of area-level socioeconomic status and rural designations. Using SEER data, we identified key incident cancers diagnosed between 2000 and 2016 at age ≥20 years (N = 3,788,273), examining a 20% random sample (n = 757,655). Standardized competing risk and survival models estimated the association between rural residence, defined by Rural-Urban Continuum Codes, and cancer-specific and all-cause mortality, controlling for age at cancer diagnosis, sex, race/ethnicity, year of diagnosis, and Area Deprivation Index (ADI). We estimated the attributable fraction (AF) of rurality and high ADI (ADI > median) to the probability of mortality. Finally, we examined county measurement issues contributing to mortality rates discordant from hypothesized rates. The 5-year standardized failure probability for cancer mortality for rural patients was 33.9% versus 31.56% for urban. The AF for rural residence was 1.04% at year 1 (0.89% by year 5), the highest among local stage disease (Y1 2.1% to Y5 1.9%). The AF for high ADI was 3.33% in Y1 (2.87% in Y5), while the joint effect of rural residence and high ADI was 4.28% in Y1 (3.71% in Y5). Twenty-two percent of urban counties and 30% of rural were discordant. Among discordant urban counties, 30% were only considered urban because of adjacency to metro area. High ADI was associated with urban discordance and low ADI with rural discordance. Rural residence independently contributes to cancer mortality. The rural impact is the greatest among those with localized disease and in high deprivation areas. Rural-urban county designations may mask high-need urban counties, limiting eligibility to state and federal resources dedicated to rural areas.

Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials

BackgroundCertain populations have been historically underrepresented in clinical trials. Broadening eligibility criteria is one approach to inclusive clinical research and achieving enrollment goals. How broadened trial eligibility criteria affect the diversity of eligible participants is unknown.MethodsUsing a nationwide electronic health record–derived deidentified database, we identified a retrospective cohort of patients diagnosed with 22 cancer types between April 1, 2013 and December 31, 2022 who received systemic therapy (N=235,234) for cancer. We evaluated strict versus broadened eligibility criteria using performance status and liver, kidney, and hematologic function around first line of therapy. We performed logistic regression to estimate odds ratios for exclusion by strict criteria and their association with measures of patient diversity, including sex, age, race or ethnicity, and area-level socioeconomic status (SES); estimated the impact of broadening criteria on the number and distribution of eligible patients; and performed Cox regression to estimate hazard ratios for real-world overall survival (rwOS) comparing patients meeting strict versus broadened criteria.ResultsWhen applying common strict cutoffs for eligibility criteria to patients with complete data and weighting each cancer type equally, 48% of patients were eligible for clinical trials. Female (odds ratio, 1.30; 95% confidence interval [CI], 1.25 to 1.35), older (age 75+ vs. 18 to 49 years old: odds ratio, 3.04; 95% CI, 2.85 to 3.24), Latinx (odds ratio, 1.46; 95% CI, 1.39 to 1.54), non-Latinx Black (odds ratio, 1.11; 95% CI, 1.06 to 1.16), and lower-SES patients were more likely to be excluded using strict eligibility criteria. Broadening criteria increased the number of eligible patients by 78%, with the strongest impact for older, female, non-Latinx Black, and lower-SES patients. Patients who met only broadened criteria had worse rwOS versus those with strict criteria (hazard ratio, 1.31; 95% CI, 1.27 to 1.34).ConclusionsData-driven evaluation of clinical trial eligibility criteria may optimize the eligibility of certain historically underrepresented groups and promote access to more inclusive trials. (Sponsored by Flatiron Health.)

Abstract PR-009: Associations between PM2.5, vegetation density and childhood brain tumors: a case-control registry-based study from Texas 1995-2011

Abstract Background: Air pollution has been reported to be associated with some childhood cancers, namely leukemias. Less is known about air pollution and childhood brain tumor risk. In adult cancers, increasing vegetation density, or greenness, has been inversely associated with cancer incidence and survival. The interplay between air pollution and greenness, which co-occur, in childhood cancer etiology is unclear. Therefore, we sought to estimate the association between prenatal and early life exposure to air pollution, greenness, and childhood cancer in Texas (1995-2011). Materials and Methods: We included 1,316 individuals with a childhood brain tumor diagnosed <17 years of age and 109,762 age- and sex-matched controls. We linked birth certificate residential address to census tract annual average particulate matter 2.5 µg/m³ (PM2.5) and Normalized Difference Vegetation Index (NDVI) to approximate prenatal and early life exposure to greenness and air pollution. We estimated odds ratios (OR) and 95% confidence intervals (95% CI) as the measure of association between PM2.5 and NDVI interquartile range (IQR) increases and brain tumors. Models were adjusted for birth year, sex, maternal race/ethnicity, and area-level socioeconomic status (Yost index). Results: The following brain tumor types were included: ependymoma (n=136), astrocytoma (n=619), medulloblastoma (n=187), PNET (n=57), ATRT (n=54), and other gliomas (n=263). Average birth year PM2.5 and NDVI exposure levels were similar in cases and controls, 11 µg/m³ and 0.4, respectively. Each IQR increase (2.6 µg/m³) in PM2.5 was associated with ependymoma (OR: 1.27, 95% CI: 1.01-1.60) when adjusting for control-derived quartiles of NDVI. Conversely, after adjusting for PM2.5 quartiles, each IQR increase in NDVI (0.13) was inversely associated with ependymoma in those diagnosed at 0-4 years of age (OR: 0.75, 95% CI: 0.56-0.97) and with medulloblastoma in those aged 0-16 years at diagnosis (OR: 0.75, 95% CI: 0.62-0.91). There was no evidence of statistical interaction between NDVI and PM2.5 (all Likelihood Ratio Test p-values>0.05) for any brain tumors. Conclusions: Increasing residential air pollution during prenatal and early life increased the risk of childhood ependymoma in Texas independent of greenness. Conversely, increasing greenness exposure in prenatal and early life decreased the risk of ependymoma and medulloblastoma independent of PM2.5. These findings highlight the complex relationship between air pollution and greenness in childhood cancer etiology. Citation Format: Lindsay Williams, David Haynes, Jeannette Sample, Laura McGuinn, Thanh Hoang, Philip Lupo, Michael Scheurer. Associations between PM2.5, vegetation density and childhood brain tumors: a case-control registry-based study from Texas 1995-2011 [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr PR-009.

Oral antiviral utilisation among older adults with COVID-19 in primary care: A population-wide study during successive Omicron waves in Singapore

Studies have repeatedly demonstrated the real-world effectiveness of oral antivirals (OAVs) in preventing hospitalisation and death in patients with mild-to-moderate COVID-19 at high risk for progression to severe COVID-19 when initiated within 5 days of symptom onset, even during waves of Omicron transmission.1 However, there is a need to determine if OAVs are reaching recommended groups, particularly among older adults and socioeconomically disadvantaged groups at higher risk of severe COVID-19. Disparities in access to OAVs based on area-level socioeconomic status (SES) have been documented in the US, UK and Australia,2-4 with substantially lower dispensing rates reported from more deprived areas. However, to the best of our knowledge, no studies have evaluated disparities in OAV access among urbanised Asian populations, including Singapore.

Who is more vulnerable to effects of long-term exposure to air pollution on COVID-19 hospitalisation?

ObjectiveFactors that shape individuals’ vulnerability to the effects of air pollution on COVID-19 severity remain poorly understood. We evaluated whether the association between long-term exposure to ambient NO2, PM2.5, and PM10 and COVID-19 hospitalisation differs by age, sex, individual income, area-level socioeconomic status, arterial hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. MethodsWe analysed a population-based cohort of 4,639,184 adults in Catalonia, Spain, during 2020. We fitted Cox proportional hazard models adjusted for several potential confounding factors and evaluated the interaction effect between vulnerability indicators and the 2019 annual average of NO2, PM2.5, and PM10. We evaluated interaction on both additive and multiplicative scales. ResultsOverall, the association was additive between air pollution and the vulnerable groups. Air pollution and vulnerability indicators had a synergistic (greater than additive) effect for males and individuals with low income or living in the most deprived neighbourhoods. The Relative Excess Risk due to Interaction (RERI) was 0.21, 95 % CI, 0.15 to 0.27 for NO2 and 0.16, 95 % CI, 0.11 to 0.22 for PM2.5 for males; 0.13, 95 % CI, 0.09 to 0.18 for NO2 and 0.10, 95 % CI, 0.05 to 0.14 for PM2.5 for lower individual income and 0.17, 95 % CI, 0.12 to 0.22 for NO2 and 0.09, 95 % CI, 0.05 to 0.14 for PM2.5 for lower area-level socioeconomic status. Results for PM10 were similar to PM2.5. Results on multiplicative scale were inconsistent. ConclusionsLong-term exposure to air pollution had a larger synergistic effect on COVID-19 hospitalisation for males and those with lower individual- and area-level socioeconomic status.

Socio-economic status and access to fluoridated water in Queensland: an ecological data linkage study.

To investigate the relationship between access to fluoridated drinking water and area-level socio-economic status in Queensland. Ecological, geospatial data linkage study. Queensland, by statistical area level 2 (SA2), 2021. Proportion of SA2s and of residents with access to fluoridated drinking water (natural or supplemented); relationship at SA2 level between access to fluoridated water and socio-economic status (Index of Relative Socio-economic Advantage and Disadvantage, IRSAD; Index of Economic Resources, IER). In 2021, an estimated 4 050 168 people (79.4% of the population) and 397 SA2 regions (72.7%) in Queensland had access to fluoridated water. Access was concentrated in the southeastern corner of the state. After adjusting for SA2 population, log area, and population density, the likelihood of access to fluoridated drinking water almost doubled for each 100-rank increase in IRSAD (adjusted odds ratio [aOR], 1.93; 95% confidence interval [CI], 1.59-2.36) or IER (aOR, 1.77; 95% CI, 1.50-2.11). The 2012 decision to devolve responsibility for water fluoridation decisions and funding from the Queensland government to local councils means that residents in lower socio-economic areas are less likely to have access to fluoridated water than those in more advantaged areas, exacerbating their already greater risk of dental disease. Queensland water fluoridation policy should be revised so that all residents can benefit from this evidence-based public health intervention for reducing the prevalence of dental caries.

Relationship between area-level socioeconomic status and health-related quality of life among cancer survivors.

Area-level socioeconomic status (SES) impacts cancer outcomes, such as stage at diagnosis, treatments received, and mortality. However, less is known about the relationship between area-level SES and health-related quality of life (HRQOL) for cancer survivors. To assess the additive value of area-level SES data and the relative contribution of area- and individual-level SES for estimating cancer survivors' HRQOL, we conducted a secondary analysis of data from a population-based survey study of cancer survivors (the Measuring Your Health [MY-Health] Study). Multilevel multinomial logistic regression models were used to examine the relationships between individual-level SES, area-level SES as measured by the Centers for Disease Control and Prevention's Social Vulnerability Index, and HRQOL group membership (high, average, low, or very low HRQOL). Area-level SES did not significantly increase model estimation accuracy compared to models using only individual-level SES. However, area-level SES could be an appropriate proxy when the individual-level SES is missing.

Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia

Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with lower socioeconomic status (SES), People of Color (POC), and older adults. NT uptake equity in acute myeloid leukemia (AML) is not well known. We performed a retrospective cohort study (1/2014-8/2022) of the United States nationwide Flatiron HealthTM electronic health record-derived, de-identified database. We estimated sociodemographic associations with AML NT receipt using incidence rate ratios (IRR). Odds ratios (OR) assessed differences in venetoclax (the most common NT) receipt at community sites and between site characteristics and NT adoption. Of 8081 patients (139 sites), 3102 (38%) received a NT. NT use increased annually (IRR 1.14, 95% confidence interval [1.07, 1.22]). NT receipt was similar between Non-Hispanic-Whites and POC (IRR 1.03, [0.91, 1.17]) and as age increased (IRR 1.02 [0.97, 1.07]). At community sites, Non-Hispanic-Whites were less likely to receive venetoclax (OR 0.77 [0.66, 0.91]); older age (OR 1.05 [1.04, 1.05]) and higher area-level SES were associated with venetoclax receipt (OR 1.23 [1.05, 1.43]). Early NT adopting sites had more prescribing physicians (OR 1.25 [1.13, 1.43]) and higher SES strata patients (OR 2.81 [1.08, 7.66]). Inequities in AML NT uptake were seen by SES; for venetoclax, differential uptake reflects its label indication for older adults and those with comorbidities.

Area-level deprivation and individual-level socioeconomic correlates of the diabetes care cascade among black south africans in uMgungundlovu, KwaZulu-Natal, South Africa.

South Africa is experiencing a rapidly growing diabetes epidemic that threatens its healthcare system. Research on the determinants of diabetes in South Africa receives considerable attention due to the lifestyle changes accompanying South Africa's rapid urbanization since the fall of Apartheid. However, few studies have investigated how segments of the Black South African population, who continue to endure Apartheid's institutional discriminatory legacy, experience this transition. This paper explores the association between individual and area-level socioeconomic status and diabetes prevalence, awareness, treatment, and control within a sample of Black South Africans aged 45 years or older in three municipalities in KwaZulu-Natal. Cross-sectional data were collected on 3,685 participants from February 2017 to February 2018. Individual-level socioeconomic status was assessed with employment status and educational attainment. Area-level deprivation was measured using the most recent South African Multidimensional Poverty Index scores. Covariates included age, sex, BMI, and hypertension diagnosis. The prevalence of diabetes was 23% (n = 830). Of those, 769 were aware of their diagnosis, 629 were receiving treatment, and 404 had their diabetes controlled. Compared to those with no formal education, Black South Africans with some high school education had increased diabetes prevalence, and those who had completed high school had lower prevalence of treatment receipt. Employment status was negatively associated with diabetes prevalence. Black South Africans living in more deprived wards had lower diabetes prevalence, and those residing in wards that became more deprived from 2001 to 2011 had a higher prevalence diabetes, as well as diabetic control. Results from this study can assist policymakers and practitioners in identifying modifiable risk factors for diabetes among Black South Africans to intervene on. Potential community-based interventions include those focused on patient empowerment and linkages to care. Such interventions should act in concert with policy changes, such as expanding the existing sugar-sweetened beverage tax.

Abstract PR019: Evaluating the role of ambient air pollution in racial disparities of colorectal cancer incidence and survival in metropolitan Detroit

Abstract Colorectal cancer (CRC) is the third most diagnosed cancer in the United States and the third leading cause of cancer-related deaths. Moreover, Non-Hispanic Black (NHB) individuals have the highest rates of CRC incidence and mortality in the United States. We have become increasingly aware of the potential impact of social determinants of health (SDOH) on colorectal physiology and carcinogenesis. Other than individual and neighborhood level socioeconomic status (SES), neighborhood quality can also affect an individual’s risk of exposure to harmful environmental contaminants including ambient air pollution. Moreover, as NHB individuals are more likely to live in areas of lower area-level SES they experience these effects even further. We sought to understand whether higher exposure rates to fine particulate matter (PM2.5) played a role in racial differences in CRC incidence and survival in metropolitan Detroit. To do this, we obtained data from the Environmental Protection Agency (EPA) Environmental Justice Mapping and Screening Tool through the Georgetown University Environmental Impact Data Collective (EIDC) and patient data from the Metropolitan Detroit Cancer Surveillance System (MDCSS) registry. Incidence rates were calculated using population data from the American Community Survey. Associations between PM2.5 exposure and CRC incidence were estimated using Poisson modeling. Data were obtained for NHB (n=3778) and Non-Hispanic White (NHW) (n=9727) individuals diagnosed with invasive CRC between 2010 and 2019 in Wayne, Oakland, and Macomb counties, including their geocoded census tract at diagnosis as well as demographic and clinical features. Vital status was reported as months from the date of diagnosis to either death or last contact. PM2.5 metrics were converted to the national percentile of PM2.5 in the air utilizing the Bayesian space-time downscaling fusion model for derived estimates of air quality at the census tract level. Survival was assessed using Cox Proportional Hazards modeling. We found that an increase in the PM2.5 percentile increased the risk for CRC overall for NHB and NHW patients (Relative Risk [RR] = 1.80, 95% Confidence Interval [CI] = 1.55 - 2.08, p-value <0.0001). This association was even stronger among NHB patients (RR = 7.94, 95% CI = 5.45 - 11.52, p-value < 0.0001), but was not statistically significant among NHW patients (RR = 1.12, 95% CI = 0.95 – 1.32, p-value = 0.16). PM2.5 exposure was not associated with survival overall or stratified by race. We conclude that ambient air pollution, particularly PM2.5, increases the risk of CRC cancer and disproportionately affects NHB patients but may not play a role in mortality risk. These results highlight the importance of environmental justice research in biomedical research and the need for a better understanding of the etiology of CRC within and among differing genetic ancestries and races by evaluating the genetic and epigenetic differences in patient tumor samples. Citation Format: Natalie G. Snider, Theresa Hastert, Ed Peters, Elena M. Stoffel, Laura Rozek, Ann Schwartz, Kristen Purrington. Evaluating the role of ambient air pollution in racial disparities of colorectal cancer incidence and survival in metropolitan Detroit [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr PR019.

Abstract C009: Estimating the true contribution of rural residence and area deprivation on cancer mortality

Abstract Introduction True estimation of the rural effect on cancer mortality requires causal inference methodology, consideration of area-level socioeconomic status and examination of area designations (e.g., measurement of rural vs urban). Methods Utilizing Surveillance, Epidemiology and End Results data we identified key incident cancers diagnosed between 2000 and 2016 at age ≥20 (n=3,788,273). Cancer types were selected based on prior evidence of rural mortality disparities. A 20% random sample was examined (n=757,655). Rurality was defined using the Rural Urban Continuum Codes (RUCC). County indicators were linked with the Area Deprivation Index (ADI, 0 least deprived to 100 highest deprivation). Standardized competing risk and survival models estimated causal impact of rural residence on cancer-specific mortality. All models controlled for age at diagnosis, sex, race/ethnicity, year of diagnosis, and ADI. We estimated rural residence and ADI’s attributable fraction to the probability of mortality. Models were run overall and by stage. Finally, we identified county measurement issues contributing to county rates discordant from hypothesized mortality rates (i.e., urban counties with mortality>median or rural counties with mortality≤median). Results Approximately 45% were diagnosed ≥65y, 51% were female, 71% non-Hispanic white, and 12% non-Hispanic Black. Cancer diagnoses included those with screening recommendations (70%), obesity related (57%), and tobacco-related cancers (21%). The majority of patients were diagnosed with in situ or localized disease (53%). The 5y standardized failure probability for cancer-specific mortality for rural patients was 33.9% vs. 31.6% among urban. Rural + high ADI mortality was 37.9% vs. 30.7% for urban + low ADI. Rural residence attributable fraction to the probability of cancer mortality was 1.04% at Year 1, declining to 0.9% by Year 5. The rural fraction was highest among local stage disease (Y1 2.1% to Y5 1.9%). Attributable fraction of high ADI was 3.3% in Y1 to 2.9% in Y5, while the joint effect of rural+high ADI ranged from 4.3% in Y1 to 3.7% in Y5. Discordance between hypothesized and actual mortality was greater with urban/rural definitions vs ADI cut-offs (i.e., ADI distinguishes between high and low mortality better). Among 256 urban counties, 21.7% (n=89) had a higher mortality rate than hypothesized (mortality rate > median). Of those, 27 counties had no metropolitan area, but were “attached” to a nearby metro-area according to US Economic Research Service. When these 27 counties were reclassified as rural, the rural fraction was 1.4% at Y1 and 1.2% at Y5. This was a 35% and 26% relative increase, respectively. Among 349 rural counties, 15% had mortality rates higher than expected. Conclusion: Rural residence holds a small independent contribution to cancer mortality; higher among localized disease and in areas with greater deprivation. Urban/rural county designations using standard metrics may mask high need urban counties, limiting eligibility to state or federal resources dedicated to rural areas. Citation Format: Kelly Kenzik, Elizabeth Davis, Jeffrey Franks, Smita Bhatia. Estimating the true contribution of rural residence and area deprivation on cancer mortality [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C009.

Low Socioeconomic Status Confers Poorer Real-World Overall Survival for Patients with Acute Myeloid Leukemia Treated in the Modern Era

Introduction: There has been considerable growth in the treatment armamentarium of acute myeloid leukemia (AML) in the last decade. However, there is a lack of recent real-world evidence examining trends in survival amidst this rapidly changing treatment landscape. Further, prior literature has demonstrated significant heterogeneity in outcomes across different demographic groups, with scant data to understand how newer therapies have impacted survival outcomes across demographic groups in a real-world setting. The objective of this study is to describe recent trends in overall survival (rwOS) among patients with AML and to examine associations between race, ethnicity, and socioeconomic status (SES) with rwOS over time. Methods: We conducted a retrospective cohort study with data from the nationwide Flatiron health (FH) electronic health record-derived de-identified database, which is comprised of predominantly community oncology-based sites. We included patients with ≥2 visits in the FH network with a confirmed diagnosis of AML between Jan 1, 2014 and Dec 31, 2022, with potential follow-up through May 31, 2023. Our exposures included year of diagnosis in 3-year periods (2014-2016, 2017-2019, 2020-2022), race, ethnicity, and area-level SES, as measured using the Yost Index at census block group level. Patient characteristics and treatment patterns were described overall and by time periods of AML diagnosis. The Kaplan-Meier method was used to estimate median rwOS and 95% confidence intervals (CIs) from the time of initial AML diagnosis; overall and stratified by time period of AML diagnosis. Cox proportional hazards models were used to estimate unadjusted and minimally-adjusted (for age and sex) hazard ratios (HR) and 95% CIs for associations between race, ethnicity, and SES (modeled separately) with rwOS overall and by year of AML diagnosis.. Results: A total of 10,062 patients were included in the analysis. The median (IQR) age at diagnosis was 70 years (58, 78) and 57% of patients were male. Three-fourths of the study population was White, and 70% of the cohort received care at the community oncology clinic. We identified more patients ≥75 years at diagnosis in 2020-2022 versus 2014-2016 (38% vs 31%) and an overall decrease in patients who underwent hematopoietic stem cell transplant (15% vs 21%). Although the overall proportion of patients receiving any first-line treatment was similar across time periods, fewer patients received induction chemotherapy-based regimens (29%) compared to less intensive therapies (e.g., venetoclax + hypomethylating agent; 34%) in later years. There were 6,132 deaths and an overall median rwOS was 14.2 months (95% CI 13.7-14.7). Age and sex-adjusted Cox models indicated no evidence of decreased risk of death for diagnoses in 2020-2022 (HR 0.98, 95% CI 0.92-1.05) or 2017-2019 (HR 0.95, 95% CI 0.90, 1.02) compared to diagnoses in 2014-2016. Adjusted Cox models showed no statistically significant associations between race or ethnicity with survival overall and across strata of AML diagnosis time periods. Consistent associations between the lowest SES and increased risk of overall mortality among patients with AML were observed across all time periods. Patients residing in areas in the lowest quintile of SES had increased risks of death across all three time periods (2014-2016: HR 1.18, 95% CI 1.00-1.38; 2017-2019: HR 1.28, 95% CI 1.09-1.50; 2020-2022: HR 1.21, 95% CI 1.02-1.43). Conclusion: Results of this real-world study indicate that persons with AML who are in the lowest SES group are associated with increased mortality risk, and this association persists across recent time periods. Race and ethnicity were not associated with survival in this study, although sample size was limited for some groups. Despite introduction of new therapeutic options and an increased utilization of less intensive therapies, we did not observe an increase in the overall proportion of patients with AML receiving first-line treatment. Additionally, we observed no improvement in survival outcomes across these time periods in a predominantly community-based setting. Our study adds to the growing evidence on the complex health inequities in AML and supports the persistent need for tolerable and accessible therapy to improve OS in AML. Future strategies and policies are urgently needed to offset the adverse effects of low SES to further improve outcomes for all patients with AML.

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Introduction: It is increasingly recognized that racial and socioeconomic disparities play an important prognostic role and contribute to differences in outcomes in adults receiving chemotherapy for acute myeloid leukemia (AML). Structural racism has also been implicated in limiting access to allogeneic hematopoietic cell transplantation (HCT). However, it is unclear to what degree racial and socioeconomic disparities impact post-HCT outcomes of patients with AML in contemporary practice. To address this uncertainty, we investigated the impact of socioeconomic, racial, and non-biologic disparities on outcomes in a large cohort of adults with AML undergoing allogeneic HCT while in first or second morphologic remission. Methods: We identified 1,004 adults with AML (2022 ICC criteria) who underwent allogeneic HCT between 5/2006 and 10/2021 at a single large university-affiliated cancer center. Data was collected on each patient's individual socioeconomic status (SES), including occupation, insurance type, and education attainment. Distance traveled, marital status, household size, country of birth, and religious affiliation were also recorded. Each occupation was classified by the International Socio-Economic Index (ISEI), a standard index of occupational status. Area-level SES was analyzed through the Area Deprivation Index (ADI), a validated measure of socioeconomic disadvantage which corresponds to U.S. census tract measurements. Collected HCT variables include the AML treatment-related mortality score (TRM), pre-HCT flow cytometric MRD status, HLA donor status, cytogenetic risk, conditioning regimen intensity, and incidence of severe acute and chronic graft-vs-host disease. Measured outcomes include non-relapse mortality (NRM), overall survival (OS), relapse, and relapse free survival (RFS). Cause-specific hazard models were used for univariate and multivariable regression analysis and C-statistics were calculated to quantify each model's ability to predict outcomes. Results: In univariate analysis, none of the socioeconomic or non-biologic factors were significantly associated with NRM, and all had poor predictive performance, with C-statistics not exceeding 0.53 for: marital status, larger household size (i.e., patients with children), distance traveled, ISEI, ADI, insurance status, educational attainment, or country of birth. TRM score (P<0.001), non-myeloablative conditioning (P<0.001), reduced intensity conditioning (P<0.001), CR2 (P=0.017) and marital status (P=0.014) were significantly associated with NRM in a multivariable model, but predictive performance of this model was only fair (C=0.69; Table 1). Marital status was only associated with NRM after multivariable adjustment but not on univariate evaluation, possibly because married patients were, on average, older (P<0.001), more likely to be male (P<0.001), and have higher occupational status/ISEI (P<0.001) and TRM scores (P<0.001), with age and sex as likely confounders (Table 2). African American patients (n=14) were found to have worse NRM in both univariate (P=0.036) and multivariate (P=0.024) models, consistent with previously identified racial/ethnic disparities in AML cohorts. Similar results were found for SES and non-biologic variables in regards to OS, relapse, and RFS. Notable exceptions after multivariable adjustment include: ADI was significantly associated with OS (P=0.036) and RFS (P=0.044) and marital status was not significantly associated with OS or relapse. Additional analyses demonstrated that ISEI and ADI were not associated with increased TRM or HLA donor status. Finally, distance traveled decreased in HCT recipients post-2013 (P<0.003), though the number of AML-related transplants remained unchanged. Conclusion: In this retrospective, single center analysis, socioeconomic and non-biologic factors had very limited impact on outcomes following allografting for adults with AML. While reassuring, patients able to undergo allogeneic HCT are highly selected (e.g. need for caregiver, insurance, etc.) possibly accounting for this finding, as could integrated, multidisciplinary cancer care networks and longitudinal care coordination post-HCT. Further research is needed to investigate disparities among HCT-eligible patients and improve access to HCT with a focus on reducing racial/ethnic disparities.

Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia (AML)

Introduction: AML is a morbid disease with a five-year overall survival (OS) rate of 30.5%. Despite increasing treatment options and improved OS, inequities exist. Some studies cite a 3-year OS difference between Black and White AML patients (pts) at 34% versus 43% (p < 0.001) (Bhatnagar 2021). This study examines data from AML pts in community and academic centers across the United States to assess for differences in outcomes by demographic factors. Methods: This study used the nationwide Flatiron Health electronic health record derived de-identified database with a data cutoff date of June 30, 2022. Pts were over 18 years old with a diagnosis of AML were included. Pts with acute promyelocytic leukemia or therapy related AML were excluded. The primary outcome was OS defined as time between date of diagnosis and date of death or last follow up stratified by demographic factors of race, ethnicity, sex, and socioeconomic status (SES). Area-level SES is an index quintile based on an area-level measure providing insight into pts' neighborhood SES conditions with a score of 1 representing the lowest SES and 5 representing the highest (Guadamuz 2022). Secondary outcomes included first line (1L) treatment stratified by demographic factors. Results: 3338 pts were included in the analysis. 59.8% of pts were age 65 or older, 55.9% were male, and 93.5% were non-Hispanic. 75.2% reported as White, 7.9% as Black or African American, 14.7% as other and 2.1% as Asian. Table 1 highlights key demographic features of the pts with European Leukemia Net (ELN) risk stratification. With a median follow up of 3.33 years, the median OS for the population was 15.9 months (mos) (95% CI 15, 16.9). When broken down by race, median OS was 21.4mos for Asian pts (95% CI 12.6, 23), 18.4mos for Black pts (95% CI 15, 24), 15.4mos for other pts (95% CI 13.6, 18.2), and 16.1mos for White pts (95% CI 14.9, 17.1). These results were not statistically significant (p = 0.67). When stratified by age group, there was a marginally significant difference in OS with Black pts showing a decreased OS in the age group 18-40 years. Median OS for Hispanic pts was higher at 22.7mos (95% CI 17.4, 35.9) compared to non-Hispanic pts at 15.3mos (95% CI 14.4, 16.4) (p = 0.0010). Female sex was associated with improved OS at 17.7mos (95% CI 15.6, 19.3) versus 15mos for male (95% CI 13.8, 16.1) (p < 0.0001). Median OS by SES had improved OS for pts with SES status 4 or 5 at 17.2mos (95% CI 15.7, 18.6) compared to pts with SES 1 or 2 at 16.1mos (95% CI 14.1, 18.0) (p = 0.03) (Fig.1). The mediating effect of SES on race was explored using Cox regression analysis, multivariate models, mediation analysis, and multivariate logistic regression. Analysis indicated no significant mediating effect (p = 0.3142, p = 0.1377, p = 0.3929 for cde/nde, nie, and total effect respectively). 1L treatment analysis showed greater use of 7+3 in Black versus White pts (25% vs 21%) and greater use of hypomethylating agent (HMA) or HMA+venetoclax in White versus Black pts. Similar findings were seen in the Hispanic versus Non-Hispanic pts, with higher use of 7+3 in Hispanic pts (32.5% vs 21.5%). These findings will be further stratified by age group and ELN risk category. There were no significant differences in the use of 7+3, HMA or HMA+venetoclax based on SES category. Discussion: This is a population-based study of AML pts in academic and community centers. Prior studies demonstrated Black pts have worse OS versus White pts. Similarly, we saw a non-statistically significant trend of decreased OS in young Black pts compared to White pts, but no difference when comparing races when assessing patients with an age cut off of 65 years. Hispanic White pts had statistically significant improved OS versus non-Hispanic pts, a finding not noted previously. It is possible with novel regimens such as HMA/venetoclax are responsible for improved outcomes, particularly in the elderly population, although this needs to be further explored. Molecular analysis could yield additional information on the effect of certain mutations and OS. Abraham et al (2022) demonstrated structural racism played a significant role in AML treatment outcomes in pts treated at Chicago academic centers. In our study, lower SES had a negative impact on OS, even when accounting for other factors. These findings are similar to a study by Rebechi et al (2023) and reveal the need for prospective research to mitigate structural barriers to care for AML pts.

Inequities in Autologous Stem Cell Transplantation, Chimeric Antigen Receptor T-Cell Therapy and Clinical Trial Participation in Patients Receiving Second-Line and Later Multiple Myeloma Treatment

Introduction: Despite improvements in care and novel therapies for the treatment of multiple myeloma (MM), nearly all patients experience relapse. However, few real-world studies have focused on treatment inequities that occur later in the MM patient journey with subsequent lines of therapy - the setting of particular interest for salvage treatment and novel drug development. The objectives of this study were to measure receipt of autologous stem cell transplantation (ASCT), chimeric antigen receptor T-cell therapy (CAR-T) and participation in clinical trials following initiation of second-line (2L) MM treatment and to describe inequities by race/ethnicity and area-level sociodemographic factors. Methods: This was a retrospective cohort study using the nationwide, electronic health record-derived Flatiron Health de-identified database. We included patients that previously received therapy for newly diagnosed MM and were initiating 2L between 2011 and 2023. The exposures of interest were race/ethnicity and area-level (census block group) socioeconomic status (SES) measured by the Yost index. Outcomes of interest were receipt of ASCT, CAR-T and clinical trial participation. Patients were followed from the date of 2L initiation until the first of the outcome of interest, death or end of the study period. Multivariable cause-specific hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations with receipt of ASCT, CAR-T and clinical trial participation separately and as a single outcome. Informed by the Institute of Medicine's framework for healthcare disparities, models were adjusted for clinical factors, specifically, age, sex, and Eastern Cooperative Oncology Group (ECOG) performance status. Results: In a cohort of 2,017 patients with MM that were ASCT and CAR-T naïve with a median age of 72 years (interquartile range [IQR] 63-79), 52% were male, 52% had ECOG scores of 0 or 1, and 59% were treated in community oncology practices. Prior to 2L, 73% received fluorescence in situ hybridization testing for cytogenetic abnormalities and most patients received either doublet (34%) or triplet (51%) therapy. The majority of patients included were non-Latinx (NL)-White (61%), 21% were NL-Black and 4% were Latinx. Compared to NL-White patients, fewer NL-Black patients received FISH testing (70% versus 73%) and either doublet or triplet therapy (81% versus 86%) for newly diagnosed MM. A higher proportion of Black and Latinx patients resided in areas in the lowest quintile of SES (42% and 40% respectively) compared to NL-White patients (8%). Overall, 12.7% received ASCT, 0.8% received CAR-T and 1.3% participated in a clinical trial following the start of 2L. Compared with NL-White patients, Black and Latinx patients had lower rates of treatment with ASCT and CAR-T; and clinical trial participation was also lower among Latinx patients relative to NL-White patients (see Figure). Patients living in the highest quintile of SES had higher rates of ASCT (19.2%), CAR-T (0.8%) and clinical trial participation (2.3%) compared to those living in the lowest quintile of SES (10.1%, 0.3% and 1.5% respectively). In multivariable models, NL-Black (HR 0.57, 95% CI 0.42-0.76) and Latinx (HR 0.41, 95% CI 0.25-0.76) patients had a lower likelihood of receiving these treatments or participating in a clinical trial compared to NL-White patients; similarly, living in the lowest SES quintile (HR 0.38, 95% CI 0.26-0.56) was also associated with lower likelihood of these outcomes. Other area-level factors associated with inequities in ASCT, CAR-T and trial participation included living in segregated Black neighborhoods and areas with greater concentration of non-citizen residence and no vehicle ownership. Conclusion: We observed lower receipt of ASCT, CAR-T, and participation in clinical trials among Black and Latinx patients initiating 2L or later MM therapy, as well as patients living in areas of low SES. Persistent inequities in MM span the entirety of the patient journey, including the limited uptake and availability of novel therapies at later stages of the disease and a lack of representation in trials investigating new MM therapies.

Lifestyle factors as mediators of area-level socioeconomic differentials in mental health and cognitive function: the Tromsø Study

IntroductionLow socioeconomic status (SES) is associated with poor mental health and cognitive function. Individual-level SES and area-level SES (ASES) may affect mental health and cognitive function through lifestyle. We aimed...

EPID-29. ASSOCIATIONS BETWEEN PM2.5, VEGETATION DENSITY AND CHILDHOOD BRAIN TUMORS: A CASE-CONTROL REGISTRY-BASED STUDY FROM TEXAS 1995-2011

Abstract BACKGROUND Air pollution has been reported to be associated with childhood leukemia, and increasing vegetation density (greenness) has been inversely associated with adult cancer incidence. However, the interplay between air pollution and greenness in childhood brain tumor (CBT) etiology is unclear. We sought to estimate the association between prenatal exposure to air pollution, greenness, and CBTs in Texas (1995-2011). Materials and METHODS We included 1,316 individuals with a CBT diagnosed ≤ 16 years of age and 109,762 age- and sex-matched controls. We linked birth certificate residential address to census tract annual average particulate matter 2.5 µg/m³ (PM2.5) and Normalized Difference Vegetation Index (NDVI) to approximate prenatal exposure to air pollution and greenness. We estimated odds ratios (OR) and 95% confidence intervals (95% CI) between CBTs, PM2.5 and NDVI interquartile range (IQR) increases. Models were adjusted for birth year, sex, race/ethnicity, and area-level socioeconomic status. RESULTS Ependymoma (n=136), astrocytoma (n=619), medulloblastoma (n=187), PNET (n=57), ATRT (n=54), and other gliomas (n=263) were included. Average birth year PM2.5 and NDVI exposure levels were similar in cases and controls, 11 µg/m³ and 0.4, respectively. Each IQR increase (2.6µg/m³) in PM2.5 was associated with ependymoma (OR: 1.27, 95% CI: 1.01-1.60), adjusting for NDVI. After adjusting for PM2.5 quartiles, each IQR increase in NDVI (0.13) was inversely associated with ependymoma in those diagnosed at 0-4 years of age (OR: 0.75, 95% CI: 0.56-0.97) and medulloblastoma in those aged 0-16 years at diagnosis (OR: 0.75, 95% CI: 0.62-0.91). There was no evidence of statistical interaction for any CBT. CONCLUSIONS Increasing air pollution during the prenatal period increased risk of childhood ependymoma, independent of greenness. Conversely, increasing greenness prenatal exposure decreased the risk of ependymoma and medulloblastoma, independent of PM2.5. These findings highlight the complex relationship between air pollution and greenness in CBT etiology.

Socioeconomic differences in associations between living in a 20-min neighbourhood and diet, physical activity and self-rated health: Cross-sectional findings from ProjectPLAN

The 20-min neighbourhood (20MN) concept aims to enable residents to meet daily needs using resources within a 20-min trip from home noting that there is no single definition of what services and amenities are required for daily needs nor what modes of transport constitute a 20 min trip. Whether 20MNs promote better health and whether associations differ by socio-economic status (SES) is unknown. Using cross-sectional data from adults randomly sampled in 2018-19 from Melbourne or Adelaide, Australia, we examined whether associations between neighbourhood type (20MN/non-20MN) and diet, physical activity or self-rated health vary according to individual- or area-level SES. We found no consistent patterns of interactions. The results do not consistently support the often assumed belief that 20MNs support more healthful behaviour and that these relationships vary by SES.

The distribution of registered occupational therapists, physiotherapists, and podiatrists in Australia.

In Australia, the distribution of occupational therapists, physiotherapists, and podiatrists density (per 10,000 population) by measure of location/rurality, usual resident population, and area-level socioeconomic status has not been described. To describe the national as well as states-and territories-wide distribution of registered allied health workforce-occupational therapists, physiotherapists, and podiatrists-by measures of rurality and area-level socioeconomic position in Australia. A linked data study that brings together (1) the location of health practitioners' principal place of practice from the Australian Health Practitioner Regulation Agency, (2) a measure of location/rurality-Modified Monash Model (MMM), and (3) an area-level measure of socioeconomic status-Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD). The provider-to-population ratio (i.e., density) of three Australia's allied health workforce (occupational therapists, physiotherapists, and podiatrists) was calculated according to the MMM classifications (i.e., Modified Monash 1-7) and IRSAD quintiles at state and national level. Nationwide, the density of occupational therapists and physiotherapists was highest in metropolitan areas (Modified Monash 1) and decreased with the increasing levels of the MMM categories. The national density of podiatrists was highest in Modified Monash 3 areas. The density of occupational therapists, physiotherapists, and podiatrists was highest in areas with IRSAD quintile 5 (i.e., the highest socioeconomic position) and decreased with the declining levels of the IRSAD quintiles nationwide. Moreover, there were notable disparities in the density of occupational therapists, physiotherapists, and podiatrists across each state and territory in Australia when stratified by the MMM classifications and IRSAD quintiles. There was uneven distribution of registered occupational therapists, physiotherapists, and podiatrists when stratified by measures of location/rurality and area-level socioeconomic status across Australian jurisdictions. The density of these three groups of allied health workforce tended to be more concentrated in metropolitan and most advantaged areas while remote and most disadvantaged areas exhibited less allied health workforce distribution across each state and territory.